Stellungnahme der DGS zu Abemaciclib (Verzenios^®)

• Literatur

• 1 Weide R, Feiten S, Friesenhahn V. et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus 2014; 3: 535
• 2 Gennari A, Conte P, Rosso R. et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104: 1742-1750
• 3 Joy AA, Ghosh M, Fernandes R. et al. Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol 2015; 22 (Suppl. 01) S29-S42
• 4 Partridge AH, Rumble RB, Carey LA. et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32: 3307-3329
• 5 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF. Im Internet: www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ . Stand: 29.4.2019
• 6 Cardoso F, Costa A, Senkus E. et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28: 3111
• 7 Rugo HS, Rumble RB, Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103
• 8 Cardoso F, Bischoff J, Brain E. et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013; 39: 457-465
• 9 Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 2016; 45: 129-138
• 10 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
• 11 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
• 12 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
• 13 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
• 14 Taylor CW, Green S, Dalton WS. et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16: 994-999
• 15 AstraZeneca, Fachinformation Zoladex® (Goserelin) 3,6 mg Implantat. Stand April 2015
• 16 Hartkopf AD, Huober J, Volz B. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. Breast 2018; 37: 42-51
• 17 Arbeitsgemeinschaft Gynäkologische Onkologie e.V. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer – Version 1. 2018 Im Internet: https://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2018-03/EN/Gesamt_PDF_Englisch/Updated_Guidelines_2018.pdf . Stand: 29.4.2019
• 18 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018; 37: 154-160
• 19 Fasching PA, Esteva FJ, Pivot X. et al. Patient-reported outcomes in advanced breast cancer treated with ribociclib + fulvestrant: results from MONALEESA-3. Ann Oncol 2018;
• 20 Schnipper LE, Davidson NE, Wollins DS. et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol 2016; 34: 2925-2934
• 21 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
• 22 Sledge Jr GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
• 23 Lilly, Dossier zur Nutzenbewertung gemäß § 35a SGB V – Palbociclib (IBRANCE®) – Modul 1. Im Internet: https://www.g-ba.de/downloads/92-975-1740/2016-11-22_Palbociclib_Modul1.pdf . Stand: 26.10.2018
• 24 Harbeck N, Vázquez RV, Franke F. et al. Ribociclib + tamoxifen or a non-steroidal aromatase inhibitor in premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 patient-reported outcomes. ESMO Jahrestagung, 2018. Im Internet: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Ribociclib-RIB-tamoxifen-TAM-or-a-non-steroidal-aromatase-inhibitor-NSAI-in-premenopausal-patients-pts-with-hormone-receptor-positive-HR-HER2-negative-HER2-advanced-breast-cancer-ABC-MONALEESA-7-patient-reported-outcomes-PROs . Stand: 29.4.2019